Conflicts of Interests
Correct at May 2024
COPD-X Committee
The COPD-X Guidelines Committee is responsible for updating the COPD-X Guidelines. All below-named members of the COPD-X Guidelines Committee are required to lodge declarations of potential conflicts of interest with Lung Foundation Australia on an annual basis. Such disclosures include the receipt of unrestricted educational grants, sponsorship, consultancy or other affiliations with the pharmaceutical, medical equipment or diagnostic industries.
Each committee member has a volunteer role in the COPD-X Guidelines Committee for Lung Foundation Australia (http://lungfoundation.com.au/), a not-for-profit public benevolent institution.
Committee Member |
Conflict of interest declaration |
|
Professor Ian Yang, MBBS(Hons), PhD, FRACP, Grad Dip Clin Epid, FAPSR, FThorSoc, Thoracic Physician, The Prince Charles Hospital and The University of Queensland, Brisbane, QLD (Co-Chair) |
Employee of The Prince Charles Hospital (Metro North Health, Queensland Health) and The University of Queensland.
Project grants and fellowships, paid to his institutions, from the following sources:
Editorial Board member of Respirology, Annals of the American Thoracic Society, Respiratory Medicine Today, Journal of Thoracic Disease and Cochrane Collaboration. Volunteer role in Lung Foundation Australia’s COPD Clinical Advisory Committee. He declares that he has not received consultancy fees or honoraria from pharmaceutical companies and has not acted as a member of advisory boards for pharmaceutical companies. |
|
Associate Professor Eli Dabscheck, MBBS, M Clin Epi, FRACP, Respiratory and Sleep Physician, Department of Respiratory Medicine, The Alfred Hospital, Melbourne, VIC (Co-Chair) |
No conflicts to declare |
|
Associate Professor Johnson George, BPharm, MPharm, PhD, Grad Cert Higher Education, Associate Professor, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC |
Senior Lecturer at Monash University, who is his primary employer.
Research funding from Pfizer and Boehringer Ingelheim via an investigator‐initiated research grant; and funding from GSK via investigator‐sponsored grant and consultation fee for unrelated research, paid to his primary employer (Monash University). In‐kind support from Vitalograph®, the manufacturers of COPD‐6TM, for research. He has received no personal payments from these organisations. |
|
Dr Renae McNamara, PhD, BAppSc(Phty), Clinical Specialist Physiotherapist, Prince of Wales Hospital, Sydney, NSW |
No conflicts to declare |
|
Professor Christine F McDonald, AM, FAHMS, MBBS(Hons), PhD, FRACP, FThorSoc, Director, Department of Respiratory and Sleep Medicine, The Austin Hospital, Melbourne, VIC |
Professor McDonald is a Board Medical Director for the Institute for Breathing and Sleep. She has received speakers fees from Astra Zeneca and Menarini paid to her primary employer (fee to Austin Health). She has received in kind support for oxygen trials from Air Liquide (oxygen and sham oxygen). |
|
Professor Vanessa McDonald, DipHlthScien (Nurs), BNurs, PhD, FThorSoc, Professor of Chronic Disease and Academic Clinical Nurse Consultant, The University of Newcastle and John Hunter Hospital, Newcastle, NSW |
Consultancy fees from GlaxoSmithKline (GSK) related to a Treatable Traits Steering Committee. Speaker and advisory board fees from GSK, Astra Zeneca, Menarini and Boehringer Ingelheim. |
|
Professor Brian Smith, MBBS, Dip Clin Ep & Biostats, PhD, FRACP, Staff Specialist, Bendigo Hospital, Bendigo, VIC |
No conflicts to declare |
|
Professor Nick Zwar, MBBS, MPH, PhD, FRACGP, Executive Dean, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD |
Board Member, Gold Coast Hospital and Health Service Executive Dean, Faculty of Health Sciences and Medicine, Bond University Chair, Guidelines Group, National Asthma Council |